OPAL2 Study
Evaluating the User Experience with Omnipod 5 - Type 1 Diabetes
Purpose
We are inviting adults living with type 1 diabetes to take part in the OPAL2 study. This study is wanting to understand the experience of people using the Insulet Omnipod 5 insulin pump compared to their current diabetes care.
Who can take part?
You may be eligible to participate if you are:
- Aged between 24 to 85 years
- Have been diagnosed with type 1 diabetes for at least 1 year
- Have an HbA1c of 10% or below
- Have been using insulin therapy (multiple daily injections or tubed insulin pump) for at least 3 months
- Have experience using a continuous glucose monitor (CGM)
What does participation involve?
If you choose to take part and are eligible, you will be randomly placed into one of two study groups:
- Group 1: Use the new insulin delivery system – Insulet Omnipod 5
- Group 2: Continue with your current insulin-based diabetes care. At the end of the study you will have the option of trying the Omnipod 5 for 3 months.
Participation requires your involvement in the study for at least 6-months and includes:
- 8 in-person visits at the clinical site
- Several online / remote check-ins.
Reimbursement
There is no additional cost to you as the participant in this study.
You will be reimbursed a maximum of $400 in total if you complete of all study activities.
Study Site Locations
This study is being conducted across Australia at the below hospital sites:
- St Vincent’s Public Hospital, Melbourne
- Baker Diabetes and Heart Institute, Melbourne
- Austin Hospital, Heidelberg
- Northeast Health, Wangaratta
- Southern Adelaide Diabetes and Endocrine Services, South Australia
Contact
Diabetes Technology Research Group Melbourne via email dtrg-t1research@unimelb.edu.au or call on 03 9231 2757.
This study has received ethical approval from the St Vincent’s Hospital Melbourne (Public) Human Research Ethics Committee ref# 129/25.